MRI Predicts Recurrence-Free Survival in Breast Cancer
MRI can help physicians predict breast cancer recurrence in women who underwent chemotherapy and surgery.
MRI may help predict recurrence-free survival (RFS) in women with breast cancer, even in the presence of pathologic complete response (PCR) and residual cancer burden (RCB) class, according to a study published in Radiology.
Researchers from California, Rhode Island, Pennsylvania, Washington, Alabama, South Carolina, New York, Texas, Washington DC, and Illinois, performed a prospective multicenter study to evaluate volumetric MR imaging for predicting RFS after neoadjuvant chemotherapy (NACT) of breast cancer and to consider its predictive performance relative to PCR.
The study included 162 female patients with breast tumors that were 3 cm or larger. The women were scheduled to receive NACT. They underwent four examinations with dynamic contrast-enhanced MR imaging:
1. Before NACT treatment began
2. After one cycle
3. Midtherapy
4. Before surgery[[{"type":"media","view_mode":"media_crop","fid":"47312","attributes":{"alt":"MRI","class":"media-image media-image-right","id":"media_crop_8651781788049","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"5555","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","style":"height: 135px; width: 180px; border-width: 0px; border-style: solid; margin: 1px; float: right;","title":"©nav/Shutterstock.com","typeof":"foaf:Image"}}]]
The researchers determined functional tumor volume (FTV), computed from MR images by using enhancement thresholds, and change from baseline (ÎFTV) were measured after one cycle and before surgery.
The results showed that FTV2, FTV4, and ÎFTV4 had significant association with RFS, as did HR/HER2 status and RCB class. “PCR approached significance at univariate analysis and was not significant at multivariate analysis,” the authors wrote.
The FTV2 and RCB class had the strongest predictive performance, greater than for FTV4 and PCR. At multivariate analysis, a model with FTV2, ÎFTV2, RCB class, HR/HER2 status, age, and race had the highest C statistic (0.72; 95% CI: 0.60, 0.84).
The researchers concluded that using MR imaging to measure breast tumor FTV is a strong predictor for RFS.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.
Multinational Study Reaffirms Value of Adjunctive AI for Prostate MRI
June 16th 2025The use of adjunctive AI in biparametric prostate MRI exams led to 3.3 percent and 3.4 percent increases in the AUC and specificity, respectively, for clinically significant prostate cancer (csPCa) in a 360-person cohort drawn from 53 facilities.
